RAN and ELE, novel sodium channel inhibitors that exhibit greater potency and selectivity than class Ib antiarrhythmic agents for late INa, have been shown to shorten the QTc interval in animal models and in patients with LQT3 (Chorin et al., 2016; Rajamani et al., 2016). This evidence concerns the gene RAN and long QT syndrome 3.